XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT

XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.06.2025

The following instruments on Boerse Frankfurt do have their last trading day on 16.06.2025
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.06.2025

ISIN Name
GB00BLNNFY18 HARMONY ENERGY INCOME TR.
LU0039632921 UNIRENTACORP INH. A
LU0055734320 UNIRESERVE: EURO A
LU0059863547 UNIRESERVE: USD
LU0192293511 UNIEURORENTA REAL ZINS A
LU0192294089 UNIEURORENTA REAL -NET-A
LU0247467987 UNIRESERVE:EO-CORPORATES
NL0012170237 PLAYA HOTELS+RES. EO -,10
SE0014855292 READLY INTERNATIONAL AB
US23344D1081 DADA NEXUS LTD ADS
US31572Q8087 FIBROGEN INC. DL-,01
US3498531017 FORWARD AIR CORP. DL-,01
US75382E1091 RAPT THERAP. INC.DL-,0001
US81728A1088 SENSEI BIOTHER. DL -,0001

Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!

Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.

Hier klicken

Zeit	Aktuelle Nachrichten
21.01.	Stifel raises Forward Air stock price target to $32 on asset-light LTL model
06.11.25	Forward Air: Jefferies senkt Kursziel wegen Marktvolatilität auf 30 US-Dollar
06.11.25	Forward Air stock price target lowered to $30 by Jefferies on market volatility
06.11.25	Forward Air says strategic review, potential sale still on track
06.11.25	Forward Air outlines ongoing strategic review and cost initiatives as consolidated EBITDA reaches $78M in Q3 2025

Zeit

Aktuelle Nachrichten

21.01.

Stifel raises Forward Air stock price target to $32 on asset-light LTL model

06.11.25

Forward Air: Jefferies senkt Kursziel wegen Marktvolatilität auf 30 US-Dollar

06.11.25

Forward Air stock price target lowered to $30 by Jefferies on market volatility

06.11.25

Forward Air says strategic review, potential sale still on track

06.11.25

Forward Air outlines ongoing strategic review and cost initiatives as consolidated EBITDA reaches $78M in Q3 2025

Zeit	Aktuelle Nachrichten
16.06.25	XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.06.2025		The following instruments on Boerse Frankfurt do have their last trading day on 16.06.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.06.2025ISIN NameGB00BLNNFY18 HARMONY... ► Artikel lesen

Zeit

Aktuelle Nachrichten

16.06.25

XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.06.2025

Zeit	Aktuelle Nachrichten
07.01.	FIBROGEN INC - 8-K, Current Report
07.01.	FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB
07.01.	FibroGen, Inc.: FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum	Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq... ► Artikel lesen
15.12.25	FibroGen: FDA Grants Orphan Drug Designation To Roxadustat For MDS
15.12.25	FibroGen, Inc.: Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration	Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan... ► Artikel lesen

Zeit

Aktuelle Nachrichten

07.01.

FIBROGEN INC - 8-K, Current Report

07.01.

FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB

07.01.

FibroGen, Inc.: FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq...
► Artikel lesen

15.12.25

FibroGen: FDA Grants Orphan Drug Designation To Roxadustat For MDS

15.12.25

FibroGen, Inc.: Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan...
► Artikel lesen

Zeit	Aktuelle Nachrichten
23.01.	Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals	LONDON (dpa-AFX) - This week's biotech landscape was shaped by workforce restructuring, high-profile acquisitions, and clinical trial data readouts across key therapeutic areas such as ovarian... ► Artikel lesen
22.01.	GSK To Acquire RAPT Therapeutics In $2.2 Billion Deal, Adding Long-Acting Anti-IgE Food Allergy Program
21.01.	GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout
21.01.	IN BRIEF: RTW Biotech welcomes GSK deal to buy RAPT Therapeutics
21.01.	Nach 2,2-Milliarden-Dollar-Übernahme durch GSK: Leerink Partners stuft Rapt Therapeutics herab

Zeit

Aktuelle Nachrichten

23.01.

Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals

LONDON (dpa-AFX) - This week's biotech landscape was shaped by workforce restructuring, high-profile acquisitions, and clinical trial data readouts across key therapeutic areas such as ovarian...
► Artikel lesen

22.01.

GSK To Acquire RAPT Therapeutics In $2.2 Billion Deal, Adding Long-Acting Anti-IgE Food Allergy Program

21.01.

GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout

21.01.

IN BRIEF: RTW Biotech welcomes GSK deal to buy RAPT Therapeutics

21.01.

Nach 2,2-Milliarden-Dollar-Übernahme durch GSK: Leerink Partners stuft Rapt Therapeutics herab

Zeit	Aktuelle Nachrichten
Mo	Eddie The Eagle launches Winter Olympic highlights series with Readly
Mo	Readly partners with Winter Olympic legend 'Eddie The Eagle'
29.01.	Readly beruft neue Head of Content für den DACH-Raum
19.12.25	READLY: 2025 Reading Trends: long form reading, stand alone articles and lifestyle content Brits favourite reads
17.10.25	Readly appoints Chloe Rushmere as new Head of Content UK

Zeit

Aktuelle Nachrichten

Eddie The Eagle launches Winter Olympic highlights series with Readly

Readly partners with Winter Olympic legend 'Eddie The Eagle'

29.01.

Readly beruft neue Head of Content für den DACH-Raum

19.12.25

READLY: 2025 Reading Trends: long form reading, stand alone articles and lifestyle content Brits favourite reads

17.10.25

Readly appoints Chloe Rushmere as new Head of Content UK

Zeit	Aktuelle Nachrichten
23.12.25	Sensei Biotherapeutics, Inc. - 8-K, Current Report
05.12.25	What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After-Hours Jump?
05.12.25	Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed	WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen
14.11.25	Sensei shrinks workforce by 65%, terminates 3 executive roles
14.11.25	Sensei BioTherapeutics GAAP EPS of -$3.62

Zeit

Aktuelle Nachrichten

23.12.25

Sensei Biotherapeutics, Inc. - 8-K, Current Report

05.12.25

What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After-Hours Jump?

05.12.25

Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed

WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei...
► Artikel lesen

14.11.25

Sensei shrinks workforce by 65%, terminates 3 executive roles

14.11.25

Sensei BioTherapeutics GAAP EPS of -$3.62

Unternehmen / Aktien	Kurs	%
FORWARD AIR CORPORATION	22,200	-9,76 %
HARMONY ENERGY INCOME TRUST PLC	1,070	0,00 %
KYNTRA BIO INC	6,700	+6,35 %
RAPT THERAPEUTICS INC	47,800	+0,42 %
READLY INTERNATIONAL AB	2,410	0,00 %
SENSEI BIOTHERAPEUTICS INC	9,280	+1,09 %

Unternehmen / Aktien

Kurs

FORWARD AIR CORPORATION

22,200

-9,76 %

HARMONY ENERGY INCOME TRUST PLC

1,070

0,00 %

KYNTRA BIO INC

6,700

+6,35 %

RAPT THERAPEUTICS INC